Mga Batayang Estadistika
| CIK | 1582249 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Actavia Life Sciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 ACTAVIA LIFE SCIENCE |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ |
|
| April 10, 2024 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2024 ACTAVIA LIFE SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 333-191083 39-2080103 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 10, 2024 |
Letter from Mazars USA LLP dated April 4, 2024. Exhibit 16.1 April 4, 2024 Mr. John Brancaccio Audit Committee Chair Actavia Life Sciences, Inc. 5 Penn Plaza, Floor 19 New York, NY 10001 As you may know, Mazars USA LLP (“Mazars”) is entering into a transaction with FORVIS, LLP such that by June 2024, Mazars will no longer be providing accounting and auditing services, and effective June 1, 2024, FORVIS will rebrand as Forvis Mazars, LLP (“Forvi |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 ACTAVIA LIFE SCIE |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SA |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-191083 ACTAVIA LIFE SCIENCES, I |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-S |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 ACTAVIA LIFE SCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-191083 39-2080103 (State or other jurisdiction of incorporation) (Commission |
|
| October 26, 2023 |
Exhibit 3.1 |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, I |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTIC |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-191083 RASNA THERAPEUTICS, INC. |
|
| January 23, 2023 |
Exhibit 3.1 RASNA THERAPEUTICS, INC. CERTIFICATE OF AMENDMENT ANNEX A Article III is hereby amended to read in its entirety as follows: ARTICLE III CAPITAL STOCK 3.01 Authorized Capital Stock. The total number of shares of stock this Corporation is authorized to issue one billion, five hundred and twenty million (1,520,000,000) shares. This stock shall be divided into two classes to be designated |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2023 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-191083 39-2080103 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-S |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-191083 39-2080103 (State or other jurisdiction of incorporation) (Commission F |
|
| December 20, 2022 |
Certificate of Amendment to Articles of Incorporation of Rasna Therapeutics, Inc. Exhibit 3.1 |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, I |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTIC |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-191083 RASNA |
|
| May 24, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-191083 39-2080103 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 19, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-191083 39-2080103 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 17, 2022 |
NT 10-Q 1 ea160170-nt10qrasnatherap.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2022 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-191083 39-2080103 (State or other jurisdiction of incorporation) (Commission File |
|
| March 1, 2022 |
List of Subsidiaries (incorporated by reference to Exhibit 21 to Form 10-K filed on March 01, 2022). Exhibit 21 Rasna Research, Inc., a Delaware corporation |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-191083 RASNA THERAPEUTICS, INC. |
|
| February 14, 2022 |
NT 10-Q 1 ea155669-nt10qrasnatherap.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10 |
|
| December 29, 2021 |
NT 10-K 1 ea153194-nt10krasnathera.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10 |
|
| November 30, 2021 |
Letter from Marcum LLP dated November 30, 2021 EX-16.1 2 ea151551ex16-1rasnathera.htm LETTER FROM MARCUM LLP DATED NOVEMBER 30, 2021 Exhibit 16.1 November 30, 2021 Securities and Exchange Commission 100 F Street N.E. Washington D.C. 20549 Commissioners: We have read the statements made by Rasna Therapeutics, Inc., under Item 4.01 of its Form 8-K, dated November 29, 2021. We agree with the statements concerning our Firm in such Form 8-K; we are |
|
| November 30, 2021 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-191083 39-2080103 (State or other jurisdiction of incorporation) (Commission F |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, I |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR ? |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTIC |
|
| February 16, 2021 |
NT 10-Q 1 ea135711-nt10qrasnatherape.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 1 |
|
| January 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-191083 RASNA THERAPEUTICS, INC. ( |
|
| January 15, 2021 |
EX-21 8 ex211.htm EXHIBIT 21 Exhibit 21 Rasna Research, Inc., a Delaware corporation |
|
| December 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-S |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2020 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission |
|
| October 15, 2020 |
Willy Simon Appointed as Chairman of Rasna Therapeutics, Inc. Exhibit 99.1 Willy Simon Appointed as Chairman of Rasna Therapeutics, Inc. NEW YORK—Oct. 15, 2020 (BUSINESS WIRE)-Rasna Therapeutics, Inc. (OTCQB: RASP), a development biotechnology company focused on the development of disease-modifying drugs for hematological malignancies, today announced that Willy Simon has been appointed as the Chairman of Rasna Therapeutics, replacing Alessandro Padova, who |
|
| October 15, 2020 |
8-K 1 ea128295-8krasnathera.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2020 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jur |
|
| August 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, I |
|
| August 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2020 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, |
|
| June 30, 2020 |
Exhibit 10.1 ASSET PURCHASE AGREEMENT THJS ASSET PURCHASE AGREEMENT (the "Agreement") is made and entered into as of April 16, 2020 ("Effective Date"), by and between: TIZIANA LIFE SCIENCES, PLC, a Delaware corporation ("Purchaser") and RASNA THERAPEUTICS, INC„ a Nevada corporation ("Seller"). Certain capitalized terms used in this Agreement and not defined in the body hereof are defined in Exhibi |
|
| April 24, 2020 |
Exhibit 99.1 Rasna Therapeutics Sells its Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Acute Myeloid Leukemia to Tiziana Life Sciences plc April 24, 2020 NEW YORK-Rasna Therapeutics, Inc. (OTCQB: RASP), a development stage biotechnology company focused on the development of disease-modifying drugs for hematological malignancies, today announced it has sold |
|
| April 24, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2020 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission File |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTIC |
|
| February 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2020 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission F |
|
| January 13, 2020 |
Power of Attorney (included on signature page hereto) EX-24 11 ex242.htm EXHIBIT 24 Exhibit 24 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints, jointly and severally, Kunwar Shailubhai, his attorney-in-fact, each with full power of substitution and resubstitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, an |
|
| January 13, 2020 |
Exhibit 21 Rasna Research, Inc., a Delaware corporation |
|
| January 13, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-191083 RASNA TH |
|
| December 30, 2019 |
ATVM / Active With Me Inc. NT 10-K - - NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-191083 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-S |
|
| August 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, I |
|
| July 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2019 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission File |
|
| May 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, |
|
| February 14, 2019 |
Form of 12% Convertible Promissory Note NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE AND HAS BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTIC |
|
| December 24, 2018 |
Power of Attorney (included on signature page hereto) Exhibit 24 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints, jointly and severally, Kunwar Shailubhai, his attorney-in-fact, each with full power of substitution and resubstitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhib |
|
| December 24, 2018 |
Exhibit 21 Rasna Research, Inc., a Delaware corporation |
|
| December 24, 2018 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2018 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-191083 RASNA TH |
|
| September 14, 2018 |
8-K 1 MainDocument.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2018 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of |
|
| August 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, I |
|
| August 9, 2018 |
Form of 12% Convertible Promissory Note NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE AND HAS BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| May 10, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, |
|
| April 13, 2018 |
ATVM / Active With Me Inc. CORRESP Rasna Therapeutics, Inc. 420 Lexington Avenue, Suite 2525 New York, NY 10121 April 13, 2018 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor Re: Rasna Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-224177 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securiti |
|
| April 6, 2018 |
Exhibit 4.1 RASNA THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificate 5 |
|
| April 6, 2018 |
ATVM / Active With Me Inc. FORM S-3 As filed with the Securities and Exchange Commission on April 6, 2018. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RASNA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 2834 39-2080103 (State or other jurisdiction of incorporation or organiza |
|
| April 6, 2018 |
Statement Re: Ratio Of Earnings To Fixed Charges Exhibit 12.1 STATEMENT RE: RATIO OF EARNINGS TO FIXED CHARGES The following table sets forth, for each of th |
|
| April 6, 2018 |
Form of Subordinated Indenture Exhibit 4.2 RASNA THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certif |
|
| March 26, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2018 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTIC |
|
| January 4, 2018 |
Rasna Therapeutics, Inc., Announces Follow Up Phase II Clinical Data Confirming Efficacy of Actinomycin D in Patients with NPM1-mutated Acute Myeloid Leukemia • Treatment with Actinomycin D (Act D) as a single drug achieved complete remission in 4 out of 9 evaluable patients (44.4%). • Treatment with Act D at 15 µg/kg/day for 5 days every 28 days (which defines one cycle) was well tolerated with m |
|
| January 4, 2018 |
Financial Statements and Exhibits, Other Events Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2018 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Comm |
|
| November 30, 2017 |
Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 30, 2017 |
Rasna Research, Inc., a Delaware corporation Exhibit 21 Rasna Research, Inc., a Delaware corporation |
|
| November 30, 2017 |
Exhibit 24 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints, jointly and severally, Kunwar Shailubhai, his attorney-in-fact, each with full power of substitution and resubstitution, for him in any and all capacities, to sign any and all amendments to this Interim Report on Form 10-KT, and to file the same, with exh |
|
| October 12, 2017 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2017 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Com |
|
| August 31, 2017 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2017 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Comm |
|
| August 31, 2017 |
EX-10.1 2 exhibit101.htm EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August , 2017, between Rasna Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to t |
|
| August 28, 2017 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2017 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Comm |
|
| August 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTICS, I |
|
| July 24, 2017 |
Document Rasna Therapeutics, Inc. 420 Lexington Avenue, Suite 2525 New York, NY 10170 July 24, 2017 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Attention: Jim B. Rosenberg Re: Rasna Therapeutics, Inc. Form 10-K for the Fiscal Year Ended June 30, 2016 Filed September 28, 2016 Form 10-Q for the Quarterly Period Ended September 30, 2016 Filed November 21, 2016 File N |
|
| July 6, 2017 |
Document Rasna Therapeutics, Inc. 420 Lexington Ave. Suite 2525 New York, NY 10170 July 6, 2017 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Attention: Jim B. Rosenberg Re: Rasna Therapeutics, Inc. Form 10-K for the Fiscal Year Ended June 30, 2016 Filed September 28, 2016 Form 10-Q for the Quarterly Period Ended September 30, 2016 Filed November 21, 2016 File No. 3 |
|
| June 30, 2017 |
Active With Me 10-K/A (Annual Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 R |
|
| June 30, 2017 |
Exhibit Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ? Agreement ?) is entered into effective May 24, 2017 (the ? Effective Date ?), by and between Shailubhai Kunwar (the ? Executive ?) and Rasna Therapeutics, Inc. (the ? Company ?). The Company desires to employ the Executive and, in connection therewith, to compensate the Executive for Executive?s personal |
|
| June 29, 2017 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAP |
|
| June 29, 2017 |
EX-3.2 2 a03312017rasnaexhibit32.htm EXHIBIT 3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF RASNA THERAPEUTICS, INC. (a Nevada Corporation) Adopted as of August 12, 2016 ARTICLE I OFFICES 1. Registered Office. The registered office of Rasna Therapeutics, Inc. (the “Corporation”) in the State of Nevada shall be in such location as the directors determine in the State of Nevada. 2. Other Offices. T |
|
| June 29, 2017 |
Exhibit 14 RASNA THERAPEUTICS, Inc. CODE OF BUSINESS CONDUCT AND ETHICS 1. Introduction We are committed to maintaining the highest standards of ethical, honest and legal business conduct. This Code of Business Conduct and Ethics (“Code”) reflects the business practices and principles of behavior that support this commitment. We expect all employees, including officers, and directors of Rasna Ther |
|
| June 29, 2017 |
Exhibit 21 Rasna Research, Inc., a Delaware corporation Exhibit 24 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints, jointly and severally, Kunwar Shailubhai, his attorney-in-fact, each with full power of substitution and resubstitution, for him in any and all capacities, to sign any and all amendments to this Annu |
|
| June 27, 2017 |
Document Rasna Therapeutics, Inc. 420 Lexington Ave. Suite 2525 New York, NY 10170 June 27, 2017 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Attention: Jim B. Rosenberg Re: Rasna Therapeutics, Inc. Form 10-K for the Fiscal Year Ended June 30, 2016 Filed September 28, 2016 Form 10-Q for the Quarterly Period Ended September 30, 2016 Filed November 21, 2016 File No. |
|
| June 21, 2017 |
Document Rasna Therapeutics, Inc. 420 Lexington Ave. Suite 2525 New York, NY 10170 June 21, 2017 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Attention: Jim B. Rosenberg Re: Rasna Therapeutics, Inc. Form 10-K for the Fiscal Year Ended June 30, 2016 Filed September 28, 2016 Form 10-Q for the Quarterly Period Ended September 30, 2016 Filed November 21, 2016 File No. |
|
| June 14, 2017 |
NT 10-K 1 a03312017rasnaform12b-25.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N- SAR ¨ Form N-CSR For Period Ended: March 31, 2017 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transit |
|
| June 9, 2017 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8-K 1 a8k090617.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2017 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorpor |
|
| June 5, 2017 |
Rasna Therapeutics, Inc. 420 Lexington Avenue, Suite 2525 New York, NY 10170 June 5, 2017 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Attention: Jim B. Rosenberg Re: Rasna Therapeutics, Inc. Form 10-K for the Fiscal Year Ended June 30, 2016 Filed September 28, 2016 Form 10-Q for the Quarterly Period Ended September 30, 2016 Filed November 21, 2016 File No. 333-191 |
|
| May 8, 2017 |
Exhibit Rasna Therapeutics, Inc. Advances Development of a Novel Treatment for NPM1-mutated Acute Myeloid Leukemia May 8, 2017 NEW YORK-(BUSINESS WIRE)-Rasna Therapeutics, Inc. (OTCQX: RASP), a clinical stage biotechnology company focused on the development of disease-modifying drugs for hematological malignancies, today provided an update from further studies towards the development of formulated |
|
| May 8, 2017 |
Financial Statements and Exhibits, Other Events Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2017 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commissi |
|
| April 28, 2017 |
Rasna Therapeutics, Inc. 420 Lexington Avenue, Suite 2525 New York, NY 10170 April 28, 2017 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Attention: Jim B. Rosenberg Re: Rasna Therapeutics, Inc. Form 10-K for the Fiscal Year Ended June 30, 2016 Filed September 28, 2016 Form 10-Q for the Quarterly Period Ended September 30, 2016 Filed November 21, 2016 File No. 333-1 |
|
| April 20, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2017 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-191083 39-2080103 (State or other jurisdiction of incorporation) (Commission File |
|
| April 12, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2017 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 12, 2017 |
Exhibit 99.1 Rasna Therapeutics Announces Upgrade to OTCQX? NEW YORK, NY ? April 12, 2017 ? Rasna Therapeutics, Inc. (OTCQX: RASP), a clinical-stage biotechnology company focused on delivering novel therapeutics and biomarkers for acute myeloid leukemia (AML) patients, today announced it has qualified and is now trading on the OTCQX? Best Market, operated by OTC Markets Group. The OTCQX market is |
|
| March 14, 2017 |
Active With Me FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTIC |
|
| March 14, 2017 |
Active With Me FORM 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 2) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191 |
|
| March 14, 2017 |
RASNA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Exhibit 99.1 CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets?June 30, 2016 (unaudited and restated) and March 31, 2016 2 Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended June 30, 2016 (restated) and 2015 3 Unaudited and Restated Condensed Consolidated Statement of Changes in Equity for the Three Months Ended June 30, 201 |
|
| March 14, 2017 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K /A AMENDMENT NO. 2 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2016 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-191083 39-2080103 (State or other jurisdiction (Commission Fi |
|
| March 14, 2017 |
Exhibit 99.2 Rasna Therapeutics, Inc. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial statements give effect to the Transactions (as defined below) which were consummated on August 15, 2016, pursuant to the Transaction Documents by and between the parties set out below the Transactions and gives effect to the equity offerin |
|
| March 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2017 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-191083 39-2080103 (State or other jurisdiction of incorporation) (Commission File |
|
| March 3, 2017 |
Rasna Therapeutics, Inc. 420 Lexington Avenue New York, NY 10170 March 3, 2017 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Attention: Jim B. Rosenberg Re: Rasna Therapeutics, Inc. Form 10-K for the Fiscal Year Ended June 30, 2016 Filed September 28, 2016 Form 10-Q for the Quarterly Period Ended September 30, 2016 Filed November 21, 2016 File No. 333-191083 Dear Mr |
|
| February 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form N-SAR For Period Ended: December 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ?Transition Report on Form 20-F ? Transition Report on Form N-SAR ? Transition Report on Form 11-K For the Transition Period Ended : Read attached instruction sheet before preparing form. |
|
| December 27, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2016 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission |
|
| December 27, 2016 |
Rasna Therapeutics, Inc. Closes Private Placement of $2 Million Exhibit 99.1 Rasna Therapeutics, Inc. Closes Private Placement of $2 Million December 27, 2016 Rasna Therapeutics, Inc. (OTCQB: RASP), a development stage biotechnology company focused on the development of cancer drugs, today announced that it has closed a private placement to accredited investors of an aggregate 3,366,667 shares of common stock at $0.60 per share for gross proceeds of $2.02 mill |
|
| December 27, 2016 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of December , 2016, between Rasna Therapeutics, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions |
|
| November 28, 2016 |
Exhibit 16.1 Tel: +44 (0)20 7486 5888 Fax: +44 (0)20 7487 3686 DX 9025 West End W1 www.bdo.co.uk 55 Baker Street London W1U 7EU Private and Confidential Securities and Exchange Commission 28 November 2016 100 F Street N.E. Washington D.C. 20549 Our ref: 0011282016/GH/GPD United States of America Dear Sirs: We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event th |
|
| November 28, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2016 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission |
|
| November 21, 2016 |
ATVM / Active With Me Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number 333-191083 RASNA THERAPEUTI |
|
| November 17, 2016 |
Exhibit 99.2 Rasna Therapeutics, Inc. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial statements give effect to the Transactions (as defined below) which were consummated on August 15, 2016, pursuant to the Transaction Documents by and between the parties set out below the Transactions and gives effect to the equity offerin |
|
| November 17, 2016 |
RASNA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS Exhibit 99.1 CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets?June 30, 2016 (unaudited) and March 31, 2016 2 Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended June 30, 2016 and 2015 3 Unaudited Condensed Consolidated Statement of Changes in Shareholders Equity for the Three Months Ended June 30, 2016 4 Unaudited Condensed |
|
| November 17, 2016 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2016 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333-191083 39-2080103 (State or other jurisdiction of incorporation) (Commission F |
|
| November 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form N-SAR For Period Ended: September 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR ? Transition Report on Form 11-K For the Transition Period Ended : Read attached instruction sheet before preparing form. |
|
| November 7, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2016 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission F |
|
| September 28, 2016 |
ATVM / Active With Me Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2016 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-20800103 RASNA THERAPEUTICS, INC. (Exact |
|
| September 28, 2016 |
Rasna Therapeutics, Inc., a Delaware corporation Exhibit 21 Rasna Therapeutics, Inc., a Delaware corporation |
|
| September 27, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2016 RASNA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission |
|
| September 27, 2016 |
Exhibit 99.1 Rasna Therapeutics, Inc. Announces Forward Split of Common Stock, Name Change & Ticker Change to RASP NEW YORK, NY ? September 27, 2016 ? Rasna Therapeutics, Inc. (OTCQB: RASP) (the ?Company?) (formerly Active With Me, Inc.), a development stage biotechnology company focused on the development of cancer drugs, today announced it has implemented a 3.25-for-1 forward split of its common |
|
| September 26, 2016 |
Exhibit 3.1 |
|
| September 26, 2016 | ||
| September 26, 2016 |
Active With Me FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2016 ACTIVE WITH ME, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 19, 2016 |
Exhibit 16.1 August 19, 2016 Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.E. Washington, DC 20549?7561 Re: Active With Me, Inc. We have read the statements included in Item 4.01 of Form 8?K dated August 19, 2016, of Active With Me, Inc. (the ?Registrant?), filed with the Securities and Exchange Commission and are in agreement with the statements concerning our |
|
| August 19, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2016 ACTIVE WITH ME, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 19, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2016 ACTIVE WITH ME, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 19, 2016 |
Exhibit 16.1 August 19, 2016 Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.E. Washington, DC 20549?7561 Re: Active With Me, Inc. We have read the statements included in Item 4.01 of Form 8?K dated August 19, 2016, of Active With Me, Inc. (the ?Registrant?), filed with the Securities and Exchange Commission and are in agreement with the statements concerning our |
|
| August 17, 2016 |
EX-10.1 6 a16-167281ex10d1.htm EX-10.1 Exhibit 10.1 AGREEMENT OF CONVEYANCE, TRANSFER AND ASSIGNMENT OF ASSETS AND ASSUMPTION OF OBLIGATIONS This Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (“Transfer and Assumption Agreement”) is made as of August 15, 2016, by Active With Me, Inc., a Nevada corporation (“Assignor”), and Active With Me Holdings, Inc., a |
|
| August 17, 2016 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2016 ACTIVE WITH ME, INC. (Exact Name of Registrant as Specified in Charter) Nevada 333- 191083 39-2080103 (State or other jurisdiction of incorporation) |
|
| August 17, 2016 |
Exhibit 2.1 AGREEMENT OF MERGER AND PLAN OF REORGANIZATION BY AND AMONG ACTIVE WITH ME, INC. RASNA ACQUISITION CORP. and RASNA THERAPEUTICS, INC. Dated as of August 15, 2016 1 AGREEMENT OF MERGER AND PLAN OF REORGANIZATION THIS AGREEMENT OF MERGER AND PLAN OF REORGANIZATION (this “Agreement”) is made and entered into on August 15, 2016 by and among Active With Me, Inc., a Nevada corporation (“Pare |
|
| August 17, 2016 |
Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF ACTIVE WITH ME, INC. (a Nevada Corporation) Adopted as of August 12, 2016 ARTICLE I OFFICES 1. Registered Office. The registered office of Active With Me, Inc. (the “Corporation”) in the State of Nevada shall be in such location as the directors determine in the State of Nevada. 2. Other Offices. The Corporation shall also have and maintain an office or |
|
| August 17, 2016 |
Exhibit 99.1 RASNA THERAPEUTICS LIMITED CONSOLIDATED FINANCIAL STATEMENTS AND REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM YEARS ENDED 31 MARCH 2016 AND 31 MARCH 2015 RASNA THERAPEUTICS LIMITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED 31 MARCH 2016 AND 31 MARCH 2015 CONTENTS PAGE REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM F-1 CONSOLIDATED BALANCE SHEETS F-2 CON |
|
| August 17, 2016 |
EX-99.2 10 a16-167281ex99d2.htm EX-99.2 Exhibit 99.2 Active With Me, Inc. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial statements give effect to the Transactions (as defined below) which were consummated on August 15, 2016, pursuant to the Transaction Documents by and between the parties set out below the Transactions an |
|
| August 17, 2016 |
EX-10.2 7 a16-167281ex10d2.htm EX-10.2 Exhibit 10.2 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of August 15, 2016, is made by and between ACTIVE WITH ME, Inc. a Nevada corporation (“Seller”), and each of the individuals listed under the heading “Buyers” on the signature page hereto (collectively, “Buyers”). RECITALS A. Seller owns all of the issued and outs |
|
| August 17, 2016 |
Rasna Therapeutics, Inc. - Delaware Exhibit 21 Rasna Therapeutics, Inc. - Delaware |
|
| August 17, 2016 |
Exhibit 2.2 AGREEMENT OF MERGER AND PLAN OF REORGANIZATION BY AND AMONG RASNA THERAPEUTICS, INC. FALCONRIDGE HOLDINGS LIMITED and ARNA THERAPEUTICS LIMITED Dated as of May 17, 2016 1 AGREEMENT OF MERGER AND PLAN OF REORGANIZATION THIS AGREEMENT OF MERGER AND PLAN OF REORGANIZATION (this “Agreement”) is made and entered into on May 17, 2016 by and among Rasna Therapeutics, Inc., a Delaware corporat |
|
| August 17, 2016 |
Exhibit 4.1 ACTIVE WITH ME, INC. 2016 EQUITY INCENTIVE PLAN 1. PURPOSE OF PLAN 1.1 The purpose of this 2016 Equity Incentive Plan (this ?Plan?) of Active With Me, Inc., a Nevada corporation (the ?Corporation?), is to promote the success of the Corporation and to increase stockholder value by providing an additional means through the grant of awards to attract, motivate, retain and reward selected |
|
| May 20, 2016 |
Active With Me ACTIVE WITH ME 10Q, 03.31.16 (Quarterly Report) awmi10q033116.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the quarterly period ended March 31, 2016 o Transition Report Under Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER 333-191083 ACTIVE WITH |
|
| May 16, 2016 |
Active With Me ACTIVE WITH ME 12B-25 EXTENSION FOR 10Q, 03.31.16 activewithment10q033116.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 1 |
|
| April 11, 2016 |
Active With Me ACTIVE WITH ME INC POST-EFFECTIVE AMENDMENT 2, 04.06.16 activewithmeposam2.htm As filed with the Securities and Exchange Commission on April 11, 2016 Registration Number: 333-191083 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post - Effective Amendment No. 2 To Form S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 ACTIVE WITH ME INC. (Exact Name of Registrant As Specified in its Charter) Nevada 7990 39-2080103 (St |
|
| February 17, 2016 |
Active With Me ACTIVE WITH ME 12B-25 EXTENSION FOR 10Q, 12.31.15 activewithment10q123115.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on For |
|
| February 17, 2016 |
ATVM / Active With Me Inc. 10-Q - Quarterly Report - ACTIVE WITH ME 10Q, 12.31.15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the quarterly period ended December 31, 2015 o Transition Report Under Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER 333-191083 ACTIVE WITH ME INC. (Exact |
|
| November 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q /A Amendment #1 x Quarterly Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the quarterly period ended September 30, 2015 o Transition Report Under Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER 333-191083 ACTIVE WI |
|
| November 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the quarterly period ended September 30, 2015 o Transition Report Under Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER 333-191083 ACTIVE WITH ME INC. (Exac |
|
| September 28, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2015 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-20800103 ACTIVE WITH ME INC. (Exact name |
|
| May 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the quarterly period ended March 31, 2015 o Transition Report Under Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER 333-191083 ACTIVE WITH ME INC. (Exact na |
|
| March 10, 2015 |
Active With Me ACTIVE WITH ME INC POST-EFFECTIVE AMENDMENT, 03.10.15 activewithmeposam.htm As filed with the Securities and Exchange Commission on March 10, 2015 Registration Number: 333-191083 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post - Effective Amendment No. 1 To Form S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 ACTIVE WITH ME INC. (Exact Name of Registrant As Specified in its Charter) Nevada 7990 39-2080103 (Sta |
|
| February 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the quarterly period ended December 31, 2014 o Transition Report Under Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER 333-191083 ACTIVE WITH ME INC. (Exact |
|
| November 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the quarterly period ended September 30, 2014 o Transition Report Under Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER 333-191083 ACTIVE WITH ME INC. (Exac |
|
| October 3, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2014 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-20800103 ACTIVE WITH ME INC. (Exact name |
|
| September 30, 2014 |
ATVM / Active With Me Inc. NT 10-K - - ACTIVE WITH ME 12B-25 EXTENSION FOR 10K, 06.30.14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2014 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Fo |
|
| May 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q /A Amendment #1 x Quarterly Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the quarterly period ended March 31, 2014 o Transition Report Under Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER 333-191083 ACTIVE WITH M |
|
| May 20, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the quarterly period ended March 31, 2014 o Transition Report Under Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER 333-191083 ACTIVE WITH ME INC. (Exact na |
|
| May 16, 2014 |
- ACTIVE WITH ME 12B-25 EXTENSION FOR 10Q, 03.31.14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2014 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on F |
|
| February 14, 2014 |
Active With Me ACTIVE WITH ME 10Q, 12.31.13 (Quarterly Report) activewithme10q123113.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the quarterly period ended December 31, 2013 o Transition Report Under Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER 333-191083 |
|
| December 5, 2013 |
CORRESP 1 filename1.htm ACTIVE WITH ME INC. 2005 LAKESHORE ROAD SARNIA, ONTARIO, CANADA N7X 1G4 December 5, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION 100 F Street, Washington, D.C. 20549 Attn: Jan Woo Re: Acceleration of Effective Date Active With Me Inc. Registration Statement on Form S-1 File No. 333-191083 Dear Jan Woo, Pursuant Rule 461 of the Securities Act of 1933, we hereby requ |
|
| December 5, 2013 |
- ACTIVE WITH ME INC S-1 AMENDMENT 2, 12.05.13 As filed with the Securities and Exchange Commission on December 5 , 2013 Registration Number: 333-191083 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 26, 2013 |
- ACTIVE WITH ME INC S-1 AMENDMENT 1, 11.25.13 As filed with the Securities and Exchange Commission on November 25 , 2013 Registration Number: 333-191083 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 25, 2013 |
ACTIVE WITH ME INC. 2005 LAKESHORE ROAD SARNIA, ONTARIO, CANADA N7X 1G4 November 25, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION 100F Street, Washington, D.C. 20549 Attn: Jan Woo Re: Active With Me Inc. Registration Statement on Form S-1 File No. 333-191083 In response to your letter dated October 8, 2013 we have filed an amendment to the S-1 which was originally filed on September 11, 2 |
|
| September 11, 2013 |
BYLAWS ACTIVE WITH ME INC. (the "Corporation") ARTICLE I: MEETINGS OF SHAREHOLDERS Exhibit 3.2 BYLAWS of ACTIVE WITH ME INC. (the "Corporation") ARTICLE I: MEETINGS OF SHAREHOLDERS Section 1 - Annual Meetings The annual meeting of the shareholders of the Corporation shall be held at the time fixed, from time to time, by the Board of Directors. Section 2 - Special Meetings Special meetings of the shareholders may be called by the Board of Directors or such person or persons autho |
|
| September 11, 2013 |
Registration Statement - ACTIVE WITH ME INC S-1, 09.10.13 As filed with the Securities and Exchange Commission on September 9, 2013 Registration Number: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 11, 2013 |
Exhibit 3.1 |
